Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulindac in Older AML Patients in First Complete Remission
NCT01843179Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2014
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulindac in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Primary endpoint: Efficacy of sulindac in maintaining complete remission at 2 years. Planned start Jan 2014; status: withdrawn.
02
Drugs
sulindac
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01843179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01843179.